Evidence map›Paper›PMID 40016442›Full record

ArticleNeuromolecular medicine2025

NOTCH3 Variant Position Affects the Phenotype at the Pluripotent Stem Cell Level in CADASIL.

Ana Bugallo-Casal, Elena Muiño, Susana B Bravo, Pablo Hervella, Susana Arias-Rivas, Manuel Rodríguez-Yáñez, Enrique Vara-León, Rita Quintas-Rey, Lara Pérez-Gayol, Olga Maisterra-Santos and 6 more

Abstract read
In one paragraph

Article in Neuromolecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ana Bugallo-CasalTranslational Stroke Laboratory Group (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), 15706, Santiago de Compostela, Spain.
Elena MuiñoStroke Pharmacogenomics and Genetics, Sant Pau Institute of Research (IR Sant Pau), 08041, Barcelona, Spain.
Susana B BravoProteomic Unit, Health Research Institute of Santiago de Compostela (IDIS), 15706, Santiago de Compostela, Spain.
Pablo HervellaNeuroimaging and Biotechnology Laboratory Group (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), 15706, Santiago de Compostela, Spain.
Susana Arias-RivasStroke Unit, Department of Neurology, Hospital Clínico Universitario, 15706, Santiago de Compostela, Spain.
Manuel Rodríguez-YáñezStroke Unit, Department of Neurology, Hospital Clínico Universitario, 15706, Santiago de Compostela, Spain.
Enrique Vara-LeónGalician Public Foundation of Genomic Medicine, Genomics Medicine Group, 15706, Santiago de Compostela, Spain.
Rita Quintas-ReyGalician Public Foundation of Genomic Medicine, Genomics Medicine Group, Genetic Group, Health Research Institute of Santiago de Compostela (IDIS), 15706, Santiago de Compostela, Spain.
Lara Pérez-GayolTranslational Stroke Laboratory Group (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), 15706, Santiago de Compostela, Spain.
Olga Maisterra-SantosUnidad de Memoria y Demencias, Hospital Universitario Vall d'Hebron/Vall d'Hebron Institut de Reçerca, 08035, Barcelona, Spain.
Jesús Pizarro-GonzálvezUnidad de Memoria y Demencias, Hospital Universitario Vall d'Hebron/Vall d'Hebron Institut de Reçerca, 08035, Barcelona, Spain.
María Rosa Martorell-RieraUnidad de Diagnóstico Molecular y Genética Clínica, Hospital Universitari Son Espases, 07120, Palma, Spain.
Cristòfol Vives-BauzáResearch Unit, Hospital Universitari Son Espases, IdISBa, Department of Biology, University of Balearic Islands (UIB), IUNICS, 07120, Palma, Spain.
Israel Fernández-CadenasStroke Pharmacogenomics and Genetics, Sant Pau Institute of Research (IR Sant Pau), 08041, Barcelona, Spain.
José CastilloNeuroimaging and Biotechnology Laboratory Group (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), 15706, Santiago de Compostela, Spain.
Francisco CamposTranslational Stroke Laboratory Group (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), 15706, Santiago de Compostela, Spain. francisco.campos.perez@sergas.es.

Funding

Instituto de Salud Carlos III (ISCIII) AC23-2/00029
6 · The paper itself

Abstract

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common genetic form of stroke. It is caused by a cysteine-altering variant in one of the 34 epidermal growth factor-like repeat (EGFr) domains of Notch3. NOTCH3 pathogenic variants in EGFr 1-6 are associated with high disease severity, whereas those in EGFr 7-34 are associated with late stroke onset and increased survival. However, whether and how the position of the NOTCH3 variant directly affects the disease severity remains unclear. In this study, we aimed to generate human-induced pluripotent stem cells (hiPSCs) from patients with CADASIL with EGFr 1-6 and 7-34 pathogenic variants to evaluate whether the NOTCH3 position affects the cell phenotype and protein profile of the generated hiPSCs lines. Six hiPSCs lines were generated: two from patients with CADASIL with EGFr 1-6 pathogenic variants, two from patients with EGFr 7-34 variants, and two from controls. Notch3 aggregation and protein profiles were tested in the established six hiPSCs lines. Cell analysis revealed that the NOTCH3 variants did not limit the cell reprogramming efficiency. However, EGFr 1-6 variant position was associated with increased accumulation of Notch3 protein in pluripotent stem cells and proteomic changes related with cytoplasmic reorganization mechanisms. In conclusion, our analysis of hiPSCs derived from patients with CADASIL support the clinical association between the NOTCH3 variant position and severity of CADASIL.

Indexed as

CADASILGenetic VariationInduced Pluripotent Stem CellsReceptor, Notch3AdultCells, CulturedCell SeparationFemaleHumansKaryotypingMagnetic Resonance ImagingMaleMiddle AgedProteomicsNOTCH3 protein, humanReceptor, Notch3CADASILDisease modelingHuman iPSCsNOTCH3 variant positionProteomic analysisStem cells

Identifiers

PMID40016442
PMCPMC11868349

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.